Conditions: 1 mg · four weeks · early satiety.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Why does this happen, and what would falsify the usual explanation?
four weeks at 1 mg is 28 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1 mg back by 28 days. Whether that reduces early satiety depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1 mg is 1 mg on day 1 and on day 28. A symptom driven by the rate of change has 28 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot early satiety against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Specifically, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Hold rather than escalate while symptoms are active. Always.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemSpecifically, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
In practice, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
The top of the schedule is not the target. The working dose is.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Specifically, holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Four half-lives between steps, minimum. Work it out for your agent.
edited 8 May 2026 by cake_collapsed — added the placebo-arm figures
Worth being precise here: the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.